ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2308

The Association Between Poverty and SLE Disease Burden: Experiences from a Saint Lucian Cohort

Amanda King1, Catherine Brown2, Cleopatra Altenor1, Timothy Niewold3 and Ashira Blazer3, 1Bay Medical Centre, Castries, Saint Lucia, 2The University of the West Indies, Bridgetown, Barbados, 3Hospital for Special Surgery, New York, NY

Meeting: ACR Convergence 2023

Keywords: Cohort Study, Disease Activity, risk factors, socioeconomic factors, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2257–2325) SLE – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Poverty increases non-communicable disease risk, however its influence on systemic lupus erythematosus (SLE) burden is poorly understood. Non-White racial/ethnic groups, particularly of African origin, disproportionately suffer both from SLE and poverty, making disentangling racial/ethnic vs socioeconomic influences on SLE outcomes a challenge. Saint Lucia is a Caribbean island with a predominantly African ancestry population and variable socioeconomic dynamics. We therefore tested the association between poverty and SLE severity in a unique African ancestry SLE cohort.

Methods: A 143-patient SLE cohort seeking care with the single practicing rheumatologist in Saint Lucia were included. All participants were at least 18 years old and met SLE classification criteria. Given that all rheumatology care is performed at this center, the cohort is expected to represent near-enumeration of SLE for the island population. Clinical data, demographics, and socioeconomic factors were obtained via chart review. Addresses identified district of residence, and area level poverty percentages in 2016 were obtained from the Saint Lucia National Report of Living Conditions. Incidence rates were calculated as the number of cases per 100,000 person-years of observation. The primary outcome was the Lupus Severity Index (LSI); calculated as a summation of ACR 1997 criteria multiplied by validated regression coefficients. Covariates that associated with LSI were identified by simple linear regression. Multiple regression was used to test the association between key covariates and LSI.

Results: The 2015-2018 incidence of SLE was 8 per 100,000 person-years (95% CI: 5.1-11.9). Incidence by district is shown in Figure 1. Of the 143 participants, 47 were below and 96 were above the poverty threshold. Impoverished patients were diagnosed 10 years earlier than non-impoverished patients, had lower BMIs, were more likely to live in impoverished districts, to take glucocorticoids at higher doses, and had higher lupus severity indexes than non-impoverished patients (table 1). Survival over the observation period was 85% in impoverished and 94% in non-impoverished participants (p=0.09). Linear regression models revealed associations between poverty status (p=0.002), younger age at onset (p=0.02), residence in an area with greater poverty level in 2016 (p=0.04), and higher glucocorticoid dose (p< 0.001), and greater LSI.

Conclusion: In this predominantly African ancestry SLE cohort, poverty associated with early onset SLE, higher Lupus Severity Index, and heavier reliance on glucocorticoid therapy. There were trends toward higher case fatality in impoverished participants. These data implicate socioeconomic stress in SLE disease burden and support further studies into the mechanis

Supporting image 1

A. The distribution of area level poverty by district in 2006 and 2016. D denotes district followed by the corresponding number. B. A map of Saint Lucia districts is shown with the SLE incidence by district indicated by the shading.

Supporting image 2

Values are expressed as % for categorical variables and mean ± standard deviation (SD) for continuous variables. Categorical variables compared using Fisher’s exact test; continuous variables compared using the two-sample T-test or Mann Whitney U Test. DMARDs include non-biologic agents (azathioprine, cyclophosphamide, mycophenolate mofetil, mycophenolic acid, sirolimus, tacrolimus) and biologic agents (anakinra, abatacept, belimumab, rituximab, tocilizumab). Antimalarial drugs include hydroxychloroquine or chloroquine. Glucocorticoid doses are expressed in prednisone equivalent doses. District poverty % reflects data as of 2016.


Disclosures: A. King: None; C. Brown: None; C. Altenor: None; T. Niewold: AstraZeneca, 6, Progentec, 1, S3 Connected Health, 2, Zenas, 5; A. Blazer: GlaxoSmithKlein(GSK), 2, Janssen, 2, Ucb, 2.

To cite this abstract in AMA style:

King A, Brown C, Altenor C, Niewold T, Blazer A. The Association Between Poverty and SLE Disease Burden: Experiences from a Saint Lucian Cohort [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/the-association-between-poverty-and-sle-disease-burden-experiences-from-a-saint-lucian-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-association-between-poverty-and-sle-disease-burden-experiences-from-a-saint-lucian-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology